Breaking News Instant updates and real-time market news.

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41

Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial

Celgene announced primary endpoint findings and updated results of secondary endpoints from the phase II international LAPACT trial of Abraxane plus gemcitabine in patients with locally advanced pancreatic cancer. An analysis of patients with newly diagnosed, locally advanced pancreatic cancer treated with up to 6 cycles of Abraxane plus gemcitabine as an investigational induction therapy found that patients had a median time to treatment failure of 8.8 months, which exceeded the protocol-specified target of 6.6 months. Secondary endpoints included evaluation of the disease control rate, overall response rate, progression free survival and overall survival in patients treated with an Abraxane plus gemcitabine induction therapy. One or more treatment emergent adverse event occurred in 99% of patients during induction. The most common adverse events were neutropenia, anemia and fatigue. In this prospective, phase II trial conducted in the US, Canada and Europe, patients with protocol-defined locally advanced, unresectable pancreatic cancer received an induction regimen of up to 6 cycles of Abraxane plus gemcitabine, followed by the investigator's choice of either continuation of the Abraxane plus gemcitabine regimen, treatment with chemoradiation, or surgery. More than half of patients completed the induction phase with Abraxane plus gemcitabine treatment. Forty two percent of patients did not complete induction treatment and the reasons for treatment discontinuation during induction included adverse events, progressive disease, protocol non-compliance, physician decision, death and other reasons.

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

CELG Celgene
$102.65

0.93 (0.91%)

01/17/18
JEFF
01/17/18
NO CHANGE
Target $125
JEFF
Buy
Jefferies believes $8B price tag makes sense for Juno Therapeutics
Jefferies analyst Michael Yee says that if Celgene (CELG) paid $65-$90 per share for Juno Therapeutics (JUNO), or a 50%-100% premium to the "unaffected" price before yesterday, it would equate to $7B-9B in enterprise value to consolidate. The analyst believes an $8B deal makes sense since Celgene owns 10% of Juno already. Assuming a $65-$90 per share deal price, the Street would view Juno as a positive "incremental" acquisition for Celgene, Yee tells investors in a research note. He keeps a Buy rating on Celgene with a $125 price target.
01/17/18
WELS
01/17/18
NO CHANGE
Target $63
WELS
Market Perform
Juno Therapeutics price target raised to $63 from $54 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Juno Therapeutics (JUNO) to $63 from $54 following a press report of potential acquisition interest by cell therapy partner Celgene (CELG). The analyst reiterates a Market Perform on Juno's shares.
01/17/18
CANT
01/17/18
NO CHANGE
CANT
Celgene acquisition of Juno 'doable' but questionable, says Cantor
Cantor Fitzgerald analyst Mara Goldstein maintained a Neutral rating and $112 price target on Celgene Corporation (CELG), noting that Celgene is reportedly in talks to buy the 90% of Juno Therapeutics (JUNO) that it does not already own. While Goldstein sees this potential acquisition as "doable," she questions whether it is "likely to provide a material enough offset near term to fully allay concerns regarding REVLIMID's patent expiration." In afternoon trading, Celgene shares have declined over 2.5%, while Juno shares have shot up over 49%.
01/18/18
SBSH
01/18/18
DOWNGRADE
Target $81
SBSH
Neutral
Citi downgrades Juno to Neutral, says potential takeover priced in
Citi analyst Robyn Karnauskas last night downgraded Juno Therapeutics (JUNO) to Neutral from Buy while raising her price target for the shares to $81 from $59. Juno closed yesterday up 52%, or $23.65, to $69.25 after the Wall Street Journal reported that Celgene (CELG) is in talks to acquire the company. When the story broke, Karnauskas said in a research note that Juno could be worth $110 per share in a takeover. She believes, however, that for Celgene, a deal makes sense in the $80-$85 per share range. The analyst expects Juno to trade with an M&A premium at $81 per share. With the recent 49% jump in shares, and the stock now trading within 17% of our takeover price, Karnauskas tells investors in a research note.

TODAY'S FREE FLY STORIES

SMH

Market Vectors Semiconductor

$108.93

-1.19 (-1.08%)

08:16
06/19/18
06/19
08:16
06/19/18
08:16
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QQQ

Invesco QQQ Trust

$176.50

-0.47 (-0.27%)

08:16
06/19/18
06/19
08:16
06/19/18
08:16
Technical Analysis
Invesco QQQ Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$COMP

Nasdaq Composite

$0.00

(0.00%)

08:16
06/19/18
06/19
08:16
06/19/18
08:16
Technical Analysis
Nasdaq Composite: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDX

Nasdaq 100 Index

$0.00

(0.00%)

08:16
06/19/18
06/19
08:16
06/19/18
08:16
Technical Analysis
Nasdaq 100 Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DCPH

Deciphera

$44.61

2.73 (6.52%)

08:16
06/19/18
06/19
08:16
06/19/18
08:16
Recommendations
Deciphera analyst commentary  »

Deciphera price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

CNI

Canadian National

$82.47

-0.69 (-0.83%)

08:15
06/19/18
06/19
08:15
06/19/18
08:15
Hot Stocks
CN to invest $210M to expand, strengthen Saskatchewan rail network »

CN said it plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.79

-2.78 (-0.78%)

08:15
06/19/18
06/19
08:15
06/19/18
08:15
Technical Analysis
Technical Take: Boeing falls in pre-market, breaks uptrend support line »

In pre-market trading the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APRN

Blue Apron

$3.20

0.18 (5.96%)

, REV

Revlon

$18.65

-0.2 (-1.06%)

08:15
06/19/18
06/19
08:15
06/19/18
08:15
Hot Stocks
Blue Apron appoints Alan Blake Chief Supply Chain Officer »

Blue Apron (APRN)…

APRN

Blue Apron

$3.20

0.18 (5.96%)

REV

Revlon

$18.65

-0.2 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

08:15
06/19/18
06/19
08:15
06/19/18
08:15
General news
Housing Starts Permits to be reported at 08:30 »

May Housing Starts…

08:15
06/19/18
06/19
08:15
06/19/18
08:15
General news
Housing Starts to be reported at 08:30 »

May Housing Starts will…

VLKAY

Volkswagen

$0.00

(0.00%)

, AUDVF

Audi AG

$0.00

(0.00%)

08:13
06/19/18
06/19
08:13
06/19/18
08:13
Periodicals
Jailed Audi CEO pledges to cooperate with emissions-cheating probe, WSJ reports »

CEO of Volkswagen's…

VLKAY

Volkswagen

$0.00

(0.00%)

AUDVF

Audi AG

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBCT

People's United

$18.74

0.02 (0.11%)

, FBNK

First Connecticut

$26.05

0.15 (0.58%)

08:13
06/19/18
06/19
08:13
06/19/18
08:13
Conference/Events
People's United to host conference call »

Conference call to…

PBCT

People's United

$18.74

0.02 (0.11%)

FBNK

First Connecticut

$26.05

0.15 (0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

NTRA

Natera

$14.38

0.12 (0.84%)

08:09
06/19/18
06/19
08:09
06/19/18
08:09
Hot Stocks
Natera announces research collaboration with Institut Jules Bordet »

Natera announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

BKYI

BIO-key

$2.42

0.02 (0.83%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
BIO-key awarded U.S. patent for Utilization of Biometric Data »

BIO-key International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRON

Cronos Group

$6.77

-0.25 (-3.56%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
Cronos Group granted medicinal cannabis Manufacture License in Australia »

Cronos Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CVS

CVS Health

$67.73

-2.37 (-3.38%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
CVS Pharmacy: Prescription delivery now available nationwide »

CVS Pharmacy, the retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNA

Allena Pharmaceuticals

$13.48

-0.08 (-0.59%)

08:07
06/19/18
06/19
08:07
06/19/18
08:07
Hot Stocks
Allena Pharmaceuticals completes animal proof-of-concept study for ALLN-346 »

Allena Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAT

Mattel

$17.78

0.1 (0.57%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Downgrade
Mattel rating change  »

Mattel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$14.68

2.655 (22.08%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Downgrade
Rent-A-Center rating change  »

Rent-A-Center downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXR

Citius Pharmaceuticals

$2.67

-0.03 (-1.11%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Hot Stocks
Citius Pharmaceuticals announces Mino-Lok is now a registered trademark »

Citius Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRIX

IRIDEX

$6.19

-0.91 (-12.82%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Hot Stocks
IRIDEX announces approval of CYCLO G6 Glaucoma Laser system in Korea »

IRIDEX announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, DIA

Diamonds Fund ETF

$249.72

-0.99 (-0.39%)

08:06
06/19/18
06/19
08:06
06/19/18
08:06
Technical Analysis
Technical Take: Diamonds Fund ETF breaks uptrend support line in pre-market »

As trade war and other…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

DIA

Diamonds Fund ETF

$249.72

-0.99 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSLS

ReShape Lifesciences

$3.07

-0.05 (-1.60%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Hot Stocks
ReShape Lifesciences receives issue notification for ReShape Vest patent »

ReShape Lifesciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTNB

Matinas BioPharma

$0.55

-0.0816 (-12.92%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Syndicate
Matinas BioPharma raises $8M in a public offering »

Matinas BioPharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISR

IsoRay

$0.45

0.0095 (2.16%)

08:05
06/19/18
06/19
08:05
06/19/18
08:05
Hot Stocks
IsoRay enters one-year employment contract with Lori Woods as Interim CEO »

IsoRay announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.